Published in Clin Pharmacol Ther on October 01, 1985
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol (2003) 3.34
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol (2007) 1.14
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol (1989) 1.12
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol (1989) 1.11
Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol (1989) 1.09
Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer (1989) 1.00
Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol (1990) 0.97
Pharmacokinetics of bambuterol in healthy subjects. Br J Clin Pharmacol (1998) 0.91
The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. Br J Clin Pharmacol (1991) 0.89
Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol (2005) 0.88
Genetic predisposition to lung cancer. Br J Cancer (1990) 0.88
Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol (1989) 0.88
Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol (1991) 0.87
Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase. Br J Clin Pharmacol (1998) 0.85
Elimination of toluene from venous blood and adipose tissue after occupational exposure. Br J Ind Med (1989) 0.85
Genetic testing for lung cancer risk: if physicians can do it, should they? J Gen Intern Med (2002) 0.83
Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Br J Clin Pharmacol (1988) 0.82
Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer. Environ Health Perspect (1993) 0.81
Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry (1990) 0.79
The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al., 1990) Br J Clin Pharmacol (1990) 0.79
Propafenone poisoning--a case report with plasma propafenone concentrations. J Med Toxicol (2010) 0.78
Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine. Br J Clin Pharmacol (1988) 0.78
Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Br J Clin Pharmacol (1991) 0.78
Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics. Br J Clin Pharmacol (1991) 0.77
Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol (1990) 0.77
The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect (1992) 0.76
A mapping function for man. Hum Hered (1977) 7.50
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet (2001) 6.31
Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J (1969) 4.21
Von Hippel-Lindau disease: a genetic study. J Med Genet (1991) 3.61
Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery (1993) 3.27
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology (2001) 2.85
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med (1978) 2.68
Properties of a nonjunctional current expressed from a rat connexin46 cDNA in Xenopus oocytes. J Gen Physiol (1993) 2.64
Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol (1983) 2.59
Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther (1971) 2.45
Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography. J Chromatogr (1982) 2.40
Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med Scand (1976) 2.34
Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J (1971) 2.19
Recurrence and complications after laparoscopic versus open inguinal hernia repair: results of a prospective randomized multicenter trial. Hernia (2008) 2.18
Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J (1970) 2.13
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr (1982) 2.07
Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci (1967) 2.05
Case report: epidermoid cyst of the floor of the mouth: diagnostic imaging by sonography, computed tomography and magnetic resonance imaging. Br J Radiol (1995) 1.92
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
The 11q;22q translocation: a European collaborative analysis of 43 cases. Hum Genet (1980) 1.82
Complications of tube thoracostomy for acute trauma. Am J Surg (1980) 1.78
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med (1971) 1.76
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers. Eur J Clin Pharmacol (1974) 1.68
Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med (1965) 1.67
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
Does training in a virtual reality simulator improve surgical performance? Surg Endosc (2001) 1.66
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther (1992) 1.66
Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations. J Med Genet (1971) 1.66
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun (1999) 1.66
Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother (1982) 1.65
Presumptive x-autosome translocation in a cow: preferential inactivation of the normal x chromosome. Nature (1968) 1.65
Segregation analysis of balanced pericentric inversions in pedigree data. Clin Genet (1986) 1.65
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Spo0A directly controls the switch from acid to solvent production in solvent-forming clostridia. Mol Microbiol (2000) 1.55
Maternal smoking during pregnancy and the risk of childhood cancer. Lancet (1986) 1.51
Data and theory for a revised chiasma map of man. Hum Genet (1982) 1.49
TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J (1999) 1.48
High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet (1982) 1.46
The use of fluorescence techniques for the recognition of mammalian chromosomes and chromosome regions. Int Rev Exp Pathol (1972) 1.45
Distinction between extra G-like chromosomes by quinacrine mustard fluorescence analysis. Exp Cell Res (1970) 1.44
Hypothermic effect of apomorphine in the mouse. J Pharm Pharmacol (1972) 1.43
Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42
Four patients with trisomy 8 identified by the fluorescence and Giemsa banding techniques. J Med Genet (1972) 1.42
Excursions of the cervical spine during tracheal intubation: blind oral intubation compared with direct laryngoscopy. Anaesthesia (1994) 1.41
Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clin Pharmacokinet (1977) 1.41
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther (1992) 1.41
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41
The 11q;22q translocation: a collaborative study of 20 new cases and analysis of 110 families. Hum Genet (1983) 1.40
Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci (2009) 1.39
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol (1990) 1.37
Identification of the Philadelphia chromosome as a number 22 by quinacrine mustard fluorescence analysis. Exp Cell Res (1970) 1.37
Drug utilization 90%--a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol (1998) 1.35
On the question of dose-dependent chloroquine elimination of a single oral dose. Clin Pharmacol Ther (1983) 1.34
Investigation of inheritance of chronic inflammatory bowel diseases by complex segregation analysis. BMJ (1993) 1.34
New possibilities for adrenergic modulation of ganglionic transmission. Pharmacol Rev (1966) 1.32
Pharmacokinetics of indomethacin. Clin Pharmacol Ther (1975) 1.31
Clinical pharmacology and primary health care in Europe--a gap to bridge. The WHO Working Group on Clinical Pharmacology in Europe. Eur J Clin Pharmacol (1990) 1.30
The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1975) 1.30
Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol (1997) 1.29
The yeast CDC37 gene interacts with MPS1 and is required for proper execution of spindle pole body duplication. J Cell Biol (1997) 1.28
Heterozygous expression of insulin-dependent diabetes mellitus (IDDM) determinants in the HLA system. Am J Hum Genet (1983) 1.25
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther (2001) 1.25
Clinical pharmacology and the provision of drug information. Eur J Clin Pharmacol (1992) 1.25
Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. Eur J Clin Pharmacol (1976) 1.23
A chiasma map of man. Hum Hered (1977) 1.22
Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum. Trop Med Parasitol (1986) 1.22
Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol (1985) 1.22
Determination of chloroquine and its desethyl metabolite in whole blood: an application for samples collected in capillary tubes and dried on filter paper. Ther Drug Monit (1985) 1.21
Dose-dependent absorption of amoxycillin and bacampicillin. Clin Pharmacol Ther (1985) 1.21
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol (1983) 1.21
Sonographic guidance in diagnostic and therapeutic interventions in the pleural space. AJR Am J Roentgenol (1987) 1.20
Linkage analysis in a large Swedish family supports the presence of a susceptibility locus for adenoma and colorectal cancer on chromosome 9q22.32-31.1. J Med Genet (2006) 1.18
Inheritance of migraine investigated by complex segregation analysis. Hum Genet (1995) 1.16
Translocations causing non-fluorescent Y chromosomes in human XO/XY mosaics. Hereditas (1971) 1.16
Platelet activating factor (PAF-acether): total synthesis of 1-O-octadecyl 2-O-acetyl sn-glycero-3-phosphoryl choline. FEBS Lett (1980) 1.15
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13
DNA polymorphisms within the porphobilinogen deaminase gene in two Swedish families with acute intermittent porphyria. Hum Genet (1988) 1.13
Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet (1987) 1.12
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol (1989) 1.12